Systemic Syndromes with Biomedicines

  • Giuseppe TridenteEmail author


Since the introduction of biomedicines in human therapy, a number of systemic reactions have been more frequently reported as important adverse events following treatment. Some monoclonal antibodies, interleukins, receptor inhibitors, and growth factors may preferably induce acute, violent, early events with an overall low frequency, but with serious and life-threatening capacity.



Kawasaki Disease Systemic Inflammatory Response Syndrome Progressive Multifocal Leukoencephalopathy Disseminate Intravascular Coagulation Immune Reconstitution Inflammatory Syndrome 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Clarkson B, Thompson D, Horwith M et al (1960) Cyclical edema and shock due to increased capillary permeability. Am J Med 29:193–216PubMedCrossRefGoogle Scholar
  2. 2.
    Baluna RG (2007) Cytokine-induced Vascular Leak Syndrome. Cytokines in Human Health. In: House RV, Descotes J (eds) Methods Pharmacol Toxicol. Humana Press 8:205–231Google Scholar
  3. 3.
    Olsen E, Duvic M, Frankel A et al (2001) Pivotal Phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol 19:376–388Google Scholar
  4. 4.
    Hinchey J, Chaves C, Appignani B et al (1996) A reversible posterior leukoencephalopathy syndrome. NEJM 334:494–500Google Scholar
  5. 5.
    Druey KM, Greipp PR (2010) Narrative review: the systemic capillary leak syndrome. Ann Intern Med 153:90–98PubMedCrossRefGoogle Scholar
  6. 6.
    Assaly R, Olson D, Hammersley J et al (2001) Initial evidence of endothelial cell apoptosis as a mechanism of systemic capillary leak syndrome. Chest 120:1301–1308PubMedCrossRefGoogle Scholar
  7. 7.
    Boussiotis VA, Pardo NA, Collins H et al (1996) R24 anti-GD3 ganglioside antibody can induce costimulation and prevent the induction of alloantigen-specific T cell clonal anergy. Eur J Immunol 26:149–154Google Scholar
  8. 8.
    Bajorin DF, Chapman PB, Wong G et al (1990) Phase I evaluation of a combination of monoclonal antibody R24 and interleukin 2 in patients with metastatic melanoma. Cancer Res 50:7490–7495PubMedGoogle Scholar
  9. 9.
    Hansel TT, Kropshofer H, Singer T et al (2010) The safety and side effects of monoclonal antibodies. Nat Rev Drug Discov 9:325–338PubMedCrossRefGoogle Scholar
  10. 10.
    Emminger W, Emminger-Schmidmeier W, Peters C (1990) Capillary leak syndrome during low dose granulocyte-macrophage colony-stimulating factor (rh GM-CSF) treatment of a patient in a continuous febrile state. Blut 61:219–221PubMedCrossRefGoogle Scholar
  11. 11.
    Heiss MM, Murawa P, Koralewski P et al (2010) The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial. Int J Cancer 127:2209–2221PubMedCrossRefGoogle Scholar
  12. 12.
    Bugelski PJ, Achuthanandam R, Capocasale RJ et al (2009) Monoclonal antibody-induced cytokine-release syndrome. Expert Rev Clin Immunol 5:499–521PubMedCrossRefGoogle Scholar
  13. 13.
    Getts DR, Getts MT, MaCarthy DP et al (2010) Have we overestimated the benefit of human(ized) antibodies? MAbs 2:682–694PubMedCrossRefGoogle Scholar
  14. 14.
    Eastwood D, Findlay L, Poole S et al (2010) Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4+ effector memory cells. Brit J Pharmacol 161:512–526CrossRefGoogle Scholar
  15. 15.
    Wing MG, Moreau T, Greenwood J et al (1996) Mechanism of first-dose cytokine-release syndrome by Campath 1-H: involvement of CD16 (FcγRIII) and CD11a/CD18 (LFA-1) on NK cells. J Clin Invest 98:2819–2826PubMedCrossRefGoogle Scholar
  16. 16.
    Ogoina D (2011) Fever, fever patterns and diseases called fever—A review. J Infect Pub Health 4:108–124CrossRefGoogle Scholar
  17. 17.
    Walker MR, Makropoulos AR et al (2011) Development of a human whole blood assay for prediction of cytokine release similar to anti-CD28 superagonists using multiplex cytokine and hierarchical cluster analysis. Intern Immunopharmacol 11:1697–1705CrossRefGoogle Scholar
  18. 18.
    Catumaxomab (Removab®) (2009) WA500051808 Assessment Report for removab, EMEA 32(2):195–202Google Scholar
  19. 19.
    Vogel WH (2010) Infusion reactions: diagnosis, assessment, and management. Clin J Oncol Nurs 14:10–21CrossRefGoogle Scholar
  20. 20.
    Tiu RV, Mountantonakis SE, Dunbar AJ et al (2007) Tumor lysis syndrome. Semin Thromb Hemost 33:397–407PubMedCrossRefGoogle Scholar
  21. 21.
    Will A, Thoulouli E (2011) The clinical management of tumour lysis syndrome in haematological malignancies. Brit J Haematol 154:3–13CrossRefGoogle Scholar
  22. 22.
    Howard SC, Jones DP, Pui C-H (2011) The tumor lysis syndrome. N Engl J Med 364:1844–1854PubMedCrossRefGoogle Scholar
  23. 23.
    Schlick K, Schilker G, Krisper P et al (2011) Spontaneous tumor lysis syndrome presenting as acute renal failure in an adult with de novo aleukemic T-all: value of renal biopsy? J Clin Oncol 29:494–496CrossRefGoogle Scholar
  24. 24.
    Rangel-Frausto MS, Pittet D, Costigan M et al (1995) The natural history of the systemic inflammatory syndrome (SIRS). A prospective study. JAMA 273:117–123Google Scholar
  25. 25.
    Comstedt P, Storgaard M, Lassen AT (2009) The systemic inflammatory response syndrome (SIRS) in acutely hospitalized medical patients: a cohort study. Scand J Trauma Resusc Emerg Med 17:67–72PubMedCrossRefGoogle Scholar
  26. 26.
    Jaffer U, Wade RG, Gourlay T (2010) Cytokines in the systemic inflammatory syndrome: a review. HSR Proc Intensive Care Cardiovasc Anesth 2:161–175PubMedGoogle Scholar
  27. 27.
    Bao F, Brown A, Dekaban GA et al (2011) CD11d integrin blockade reduces the systemic inflammatory response syndrome after spinal cord injury. Exp Neurol 231:271–283Google Scholar
  28. 28.
    Deane S, Selmi C, Teuber SS et al (2010) Macrophage activation syndrome in autoimmune diseases. Int Arch Allergy Immunol 153:109–120PubMedCrossRefGoogle Scholar
  29. 29.
    Dinarello CA, Simon A, van der Meer JWM (2012) Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov 11:633–652PubMedCrossRefGoogle Scholar
  30. 30.
    Lattanzi B, Davi S, Rosina S et al (2012) Macrophage activating syndrome Indian. J Rheumatol 7:27–35Google Scholar
  31. 31.
    Butin M, Mekki Y, Phan A et al (2013) Successful immunotherapy in life-threatening parvovirus B19 infection in a child. Ped Infect Dis J. doi: 10.1097/INF.0b013e31828df4d1 Google Scholar
  32. 32.
    Aronson IK, Worobec SM (2010) Cytophagic histiocytic panniculitis and hemophagocytic lymphohistiocytosis: an overview. Dermatol Ther 23:389–402PubMedCrossRefGoogle Scholar
  33. 33.
    Araki D, Fujii H, Matsumara M et al (2011) Etanercept-induced lupus accompanied by hemophagocytic syndrome. Intern Med 50:1843–1848PubMedCrossRefGoogle Scholar
  34. 34.
    Behrens EM, Kreiger PA, Cherian S et al (2006) Interleukin 1 receptor antagonist to treat cytophagic histiocytic panniculitis with secondary hemophagocytic lymphohistiocytosis. J Rheumatol 33:2081–2084PubMedGoogle Scholar
  35. 35.
    Hedrich CM, Bruck N, Flebig B (2012) Anakinra: a safe and effective first-line treatment in systemic onset juvenile idiopathic arthritis (SoJIA). Rheumatol Int 32:3525–3530PubMedCrossRefGoogle Scholar
  36. 36.
    Lin C-I, Yu H-H, Lee J-H et al (2012) Clinical analysis of macrophage activation syndrome in pediatric patients with autoimmune diseases. Clin Rheumatol 31:1223–1230PubMedCrossRefGoogle Scholar
  37. 37.
    Loh NK, Lucas M, Fernandez S et al (2012) Successful treatment of macrophage activation syndrome complicating adult Still disease with anakinra. Intern Med J. doi: 10.1111/imj.12002 Google Scholar
  38. 38.
    Murdoch DM, Venter WDF, Van Rie A et al (2007) Immune reconstitution inflammatory syndrome (IRIS): review of common infectious manifestations and treatment options. AIDS Res Ther 4:9–18PubMedCrossRefGoogle Scholar
  39. 39.
    Bush LM, Paturi A, Apuri S et al (2011) Burkitts leukemia/lymphoma as a manifestation of HIV immune reconstitution inflammatory syndrome. A review: a propos of a case. HIV & AIDS Rev 10:26–32CrossRefGoogle Scholar
  40. 40.
    Ruiz-Cruz M, Espinosa E, Romero K et al (2011) Bevacizumab reverts serous retinal detachment caused by tuberculosis-associated immune reconstitution inflammatory syndrome. AIDS 25:1241–1246PubMedCrossRefGoogle Scholar
  41. 41.
    Eltson JWT, Thaker H (2009) Immune reconstitution inflammatory syndrome. Intern J STD & AIDS 20:221–224CrossRefGoogle Scholar
  42. 42.
    Metz I, Radue E-W, Oterino A et al (2012) Pathology of immune reconstitution inflammatory syndrome in multiple sclerosis with natalizumab-associated progressive multifocal leukoencephalopathy. Acta Neuropathol 123:235–245PubMedCrossRefGoogle Scholar
  43. 43.
    Rivoisy C, Amrouche L, Carcelain G et al (2011) Paradoxical exacerbation of tuberculosis after TNF-α antagonist discontinuation: beware of immune reconstitution inflammatory syndrome. Joint Bone Spine 78:312–315PubMedCrossRefGoogle Scholar
  44. 44.
    Cadena J, Thompson III GR, Ho TT et al (2009) Immune reconstitution inflammatory syndrome after cessation of the tumor necrosis factor α blocker adalimumab in cryptococcal pneumonia. Diagn Microbiol Infect Dis 64:327–330Google Scholar
  45. 45.
    Muller PY, Milton M, Lloyd P et al (2009) The minimum anticipated biological effect level (MABEL) for selection of first human dose in clinical trials with monoclonal antibodies. Curr Op Biotechnol 20:722–729CrossRefGoogle Scholar
  46. 46.
    Sitipati AM, Kao CL, Cachay ER et al (2010) Treatment of HIV-related inflammatory cerebral cryptococcoma with adalimumab. Clin Infect Dis 50:7–10CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 2014

Authors and Affiliations

  1. 1.Department of Pathology and DiagnosticsUniversity of VeronaVeronaItaly

Personalised recommendations